Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986277 alone and with Nivolumab in advanced epithelial tumors
NCT03363776Phase 2Terminated
- Sponsor
- Bristol Myers Squibb
- Start
- Dec 2017
- Primary completion
- Nov 2019
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 2 trial of BMS-986277 in colorectal carcinoma (CRC), prostate carcinoma, pancreatic carcinoma, breast carcinoma, ovarian carcinoma, sponsored by Bristol Myers Squibb. Started Dec 2017; status: terminated.
02
Drugs
BMS-986277
03
Conditions
colorectal carcinoma (CRC)prostate carcinomapancreatic carcinomabreast carcinomaovarian carcinoma
Beyond the preview
Go deeper on NCT03363776.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03363776.